7α-Hydroxy-4-cholesten-3-one (C4) is known as a marker for the cholesterol 7α-hydroxylase activity. It plays an important role in bile acid metabolism.[1]
Application
C4 may be used as a reference standard for the determination of C4 in:
Human serum by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) with electrospray ionization source (ESI)[2] as well as LC-MS.[1]
Rat and monkey plasma by LC-ESI-MS/MS working on multiple reaction monitoring (MRM) mode of detection.[3]
Peripheral blood plasma by solid-phase extraction (SPE) and HPLC.[4]
Biochem/physiol Actions
7a-Hydroxycholestene-3-one, a metabolite in bile acid synthesis, is derived from 7a-hydroxycholesterol and can be further metabolized to 7a,12a,-dihydroxycholest-4-en-3-one. Analysis of 7a-Hydroxycholestene-3-one (HCO) in serum may serve as a novel, simple, and sensitive method for the detection of bile acid malabsorption in patients with chronic diarrhea of unknown origin.
Comparison of simple extraction procedures in liquid chromatography-mass spectrometry based determination of serum 7?-hydroxy-4-cholesten-3-one, a surrogate marker of bile acid synthesis.
Marek L, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications, 1033, 317-320 (2016)
Monitoring hepatic cholesterol 7?-hydroxylase activity by assay of the stable bile acid intermediate 7?-hydroxy-4-cholesten-3-one in peripheral blood.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1064, 49-55 (2017-09-16)
7α-hydroxy-4-cholesten-3-one (C4) is an oxidative enzymatic product of cholesterol metabolism via cholesterol 7α-hydroxylase, an enzyme also known as cholesterol 7-alpha-monooxygenase or cytochrome P450 7A1 (CYP7A1). C4 is a stable intermediate in the rate limiting pathway of bile acid biosynthesis. Previous
Clinical pharmacology in drug development, 9(3), 395-410 (2019-12-12)
Tropifexor (LJN452) is a potent, orally available, non-bile acid farnesoid X receptor agonist under clinical development for chronic liver diseases. Here, we present results from a first-in-human study of tropifexor following single- and multiple-ascending doses (SAD/MAD) and food effect substudy
A UHPLC-MS/MS method for the quantification of 7?-hydroxy-4-cholesten-3-one to assist in diagnosis of bile acid malabsorption.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.